Laekna, Inc. Advances LAE123 for Severe Diseases
Laekna, Inc. (HK:2105) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now At ...
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients ...
Business Wire7d
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obe…
Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer ...
阿思達克財經網22h
LAEKNA-B Places Shrs at 15%+ Discount to Raise $230M Net Proceeds
LAEKNA-B (02105.HK) announced that it intends to place a total of 17.636 million shares of the company, equivalent to about 4 ...
Laekna, Inc. Announces Share Placement to Raise HK$230 Million
Laekna, Inc. (HK:2105) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall Street ...
Eli Lilly in pact with Chinese biotech for novel weight loss therapy
Eli Lilly (LLY) partners with Laekna Therapeutics to develop an obesity therapy that avoids muscle loss. Read more here.
BioSpace6d
Lilly Partners With Chinese Biotech to Advance Muscle-Sparing Obesity Treatment
Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...
The Pharma Letter6d
Lilly and Laekna team up on novel obesity drugs
Eli Lilly has partnered with Laekna to advance LAE102, an antibody targeting the ActRIIA receptor, for obesity and muscle ...
阿思達克財經網7d
LAEKNA-B Last Slumps 7%+ after Announcing Shr Placing on 48% Rally Ytd
LAEKNA-B (02105.HK) -0.580 (-3.737%) announced a share placing immediately after a 48% share surge yesterday (20th). Today ...
Nasdaq8d
Laekna Partners with Eli Lilly on Obesity Drug Development
This partnership will see Lilly funding and executing a phase I study in the U.S., while Laekna retains global rights to the monoclonal antibody that targets muscle regeneration and lipid metabolism.